Overview
- 5 public-safe observations are available for this inspection.
- 5 structured CFR citations are represented.
- 3 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
16 Jun 2009
21 CFR 211.100(b)
Procedure Deviations Recorded and Justified
Cited by Christian Lynch, Paula A Trost, Lindan E Silvers
16 Jun 2009
21 CFR 211.110(b)
In-process materials specifications
Cited by Christian Lynch, Paula A Trost, Lindan E Silvers
16 Jun 2009
21 CFR 211.113(b)
Procedures for sterile drug products
Cited by Christian Lynch, Paula A Trost, Lindan E Silvers
16 Jun 2009
21 CFR 600.14(a)(1)
Who must report - manufacturer
Cited by Christian Lynch, Paula A Trost, Lindan E Silvers
Inspected site
APAstraZeneca Pharmaceuticals LPPhiladelphia, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.100(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.110(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.113(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 600.14(a)(1) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 600.14(c) | Cited across public-safe Form 483 observations | 1x |
Full 483 report
Get the verbatim text of all 5 observations
Every observation in full, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere